Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) FCF Margin (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of FCF Margin data on record, last reported at 4737.79% in Q1 2025.

  • For Q1 2025, FCF Margin changed N/A year-over-year to 4737.79%; the TTM value through Sep 2025 reached 2315.17%, down 534943.0%, while the annual FY2024 figure was 3478.99%, N/A changed from the prior year.
  • FCF Margin reached 4737.79% in Q1 2025 per RANI's latest filing, down from 844.94% in the prior quarter.
  • Across five years, FCF Margin topped out at 3594.89% in Q3 2022 and bottomed at 4737.79% in Q1 2025.
  • Average FCF Margin over 5 years is 135.05%, with a median of 944.91% recorded in 2023.
  • Peak YoY movement for FCF Margin: plummeted -249192bps in 2023, then plummeted -178985bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 284.04% in 2021, then skyrocketed by 1366bps to 3594.89% in 2022, then plummeted by -74bps to 944.91% in 2023, then tumbled by -189bps to 844.94% in 2024, then crashed by -461bps to 4737.79% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 4737.79% in Q1 2025, 844.94% in Q4 2024, and 944.91% in Q4 2023.